Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone

Tony Antoniou, Simon Hollands, Erin M. Macdonald, Tara Gomes, Muhammad M. Mamdani and David N. Juurlink; for the Canadian Drug Safety and Effectiveness Research Network
CMAJ March 03, 2015 187 (4) E138-E143; DOI: https://doi.org/10.1503/cmaj.140816
Tony Antoniou
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tantoniou@smh.ca
Simon Hollands
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin M. Macdonald
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tara Gomes
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhammad M. Mamdani
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David N. Juurlink
Department of Family and Community Medicine (Antoniou), Li Ka Shing Knowledge Institute (Antoniou, Gomes, Mamdani), St. Michael’s Hospital; University of Toronto (Gomes, Mamdani, Juurlink); Institute for Clinical Evaluative Sciences (Antoniou, Hollands, Macdonald, Gomes, Mamdani, Juurlink); Sunnybrook Research Institute (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Abstract

Background: Trimethoprim–sulfamethoxazole increases the risk of hyperkalemia when used with spironolactone. We examined whether this drug combination is associated with an increased risk of sudden death, a consequence of severe hyperkalemia.

Methods: We conducted a population-based nested case–control study involving Ontario residents aged 66 years or older who received spironolactone between Apr. 1, 1994, and Dec. 31, 2011. Within this group, we identified cases as patients who died of sudden death within 14 days after receiving a prescription for trimethoprim–sulfamethoxazole or one of the other study antibiotics (amoxicillin, ciprofloxacin, norfloxacin or nitrofurantoin). For each case, we identified up to 4 controls matched by age and sex. We determined the odds ratio (OR) for the association between sudden death and exposure to each antibiotic relative to amoxicillin, adjusted for predictors of sudden death using a disease risk index.

Results: Of the 11 968 patients who died of sudden death while receiving spironolactone, we identified 328 whose death occurred within 14 days after antibiotic exposure. Compared with amoxicillin, trimethoprim–sulfamethoxazole was associated with a more than twofold increase in the risk of sudden death (adjusted OR 2.46, 95% confidence interval [CI] 1.55–3.90). Ciprofloxacin (adjusted OR 1.55, 95% CI 1.02–2.38) and nitrofurantoin (adjusted OR 1.70, 95% CI 1.03–2.79) were also associated with an increased risk of sudden death, although the risk with nitrofurantoin was not apparent in a sensitivity analysis.

Interpretation: The antibiotic trimethoprim–sulfamethoxazole was associated with an increased risk of sudden death among older patients taking spironolactone. When clinically appropriate, alternative antibiotics should be considered in these patients.

View Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 187 (4)
CMAJ
Vol. 187, Issue 4
3 Mar 2015
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone
Tony Antoniou, Simon Hollands, Erin M. Macdonald, Tara Gomes, Muhammad M. Mamdani, David N. Juurlink
CMAJ Mar 2015, 187 (4) E138-E143; DOI: 10.1503/cmaj.140816

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone
Tony Antoniou, Simon Hollands, Erin M. Macdonald, Tara Gomes, Muhammad M. Mamdani, David N. Juurlink
CMAJ Mar 2015, 187 (4) E138-E143; DOI: 10.1503/cmaj.140816
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • A decade of outpatient antimicrobial use in older adults in Ontario: a descriptive study
  • Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation
  • Google Scholar

More in this TOC Section

  • Emergency department use following incentives to provide after-hours primary care: a retrospective cohort study
  • Physician choices in pulmonary embolism testing
  • Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study
Show more Research

Similar Articles

Collections

  • Topics
    • Nephrology
    • Pharmacology & toxicology
    • Urology
    • Drugs: cardiovascular system
    • Drugs: adverse reactions
    • Cardiology: arrhythmias
    • Drugs: antimicrobials

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire